Features of immunometabolic depression as predictors of antidepressant treatment outcomes: pooled analysis of four clinical trials

Abstract

Depressive symptoms of people with more IMD features improved less when treated with antidepressants. However, clinical relevance is limited owing to small effect sizes in inconsistent associations. Whether these patients would benefit more from treatments targeting immunometabolic pathways remains to be investigated.